Ir al contenido principal

Episodio 7. El autor prohibido

Imagen
By Dr Juan Gulin

 El autor prohibido

En este episodio espiamos que se esta haciendo en el mundo editorial con respecto al uso de los grandes modelos de lenguaje (LLM), como ChatGPT, en cuanto a su autoría en estudios de investigacion, Ademas, comentamos el Global Burden of Disease Study que muestra el peso mundial de la lumbalgia

Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 2023 May 22;5(6):e316-e329. doi: 10.1016/S2665-9913(23)00098-X. eCollection 2023 Jun.GBD 2021 Low Back Pain Collaborators . https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00098-X/fulltext

Stokel-Walker C. ChatGPT listed as author on research papers: many scientists disapprove. Nature. 2023 Jan;613(7945):620-621. doi: 10.1038/d41586-023-00107-z. PMID: 36653617. https://pubmed.ncbi.nlm.nih.gov/36653617/ 

Solomon DH, Allen KD, Katz P, Sawalha AH, Yelin E. ChatGPT, et al … Artificial Intelligence, Authorship, and Medical Publishing. ACR Open Rheumatol. 2023 Jun;5(6):288-289. doi: 10.1002/acr2.11538. Epub 2023 Apr 10. PMID: 37036239; PMCID: PMC10267801.

Entradas populares de este blog

Episodio 8. Simulando tofacitinib versus adalimumab. Datos de vida real potenciados.

By Dr Juan Gulin
 Episodio 8. Simulando tofacitinib versus adalimumab. Datos de vida real potenciados. La base de datos OPAL de Australia es una verdadera joya. Comentamos un "ensayo clinico simulado" utilizando los pacientes con AR y sus HCEs comparando tofacitinib versus adalimumab y comparamos con recomendaciones EULAR y datos de un ECA de 2017. Deakin CT , De Stavola BL , Littlejohn G, et al. Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia. JAMA Netw Open. 2023;6(6):e2320851. doi:10.1001/jamanetworkopen.2023.20851 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806589 Littlejohn  GO, Tymms  KE, Smith  T, Griffiths  HT.  Using big data from real-world Australian rheumatology encounters to enhance clinical care and research.   Clin Exp Rheumatol . 2020;38(5):874-880. https://pubmed.ncbi.nlm.nih.gov/31820719/  Fleischmann  R, Mysler ...
Read more »

Episodio 19: Primer sintoma de espondilitis

By Dr Juan Gulin
Episodio 19: Primer sintoma de espondilitis Investigadores españoles y mexicanos examinan las cohortes RESPONGISER y RESPONDIA en pos de establecer los primeros sintomas y signos de las distintas espondiloartropatias Puche-Larrubia MÁ, Ladehesa-Pineda L, Vázquez-Mellado J, et al. Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries. RMD Open 2023;9:e003235. doi: 10.1136/ rmdopen-2023-003235 E. Collantes, P. Zarco, E. Muñoz, X. Juanola, J. Mulero, J. L. Fernández-Sueiro, J. C. Torre-Alonso, J. Gratacós, C. González, E. Batlle, P. Fernández, L. F. Linares, E. Brito, L. Carmona, Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER)—extended report, Rheumatology , Volume 46, Issue 8, August 2007, Pages 1309–1315, https://doi.org/10.1093/rheumatology/kem084   Janitzia Vázquez-Mellado a , P...
Read more »

Episodio 5. Guias y vagos

By Dr Juan Gulin
 Episodio 5. Guias y vagos.  https://pod.link/1688456486 OP0234 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS. https://ard.bmj.com/content/82/Suppl_1/154   Research Update: Using Vagus Nerve Stimulation for Rheumatic Disease. April 8, 2023 • By Mary Beth Nierengarten . https://www.the-rheumatologist.org/article/research-update-using-vagus-nerve-stimulation-for-rheumatic-disease/ ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. https://clinicaltrials.gov/
Read more »